The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year.
Just 28% of U.S. adults say they have received the updated COVID-19 vaccine, which the to protect against serious illness. As coronavirus cases nationwide have plateaued, at least 20 states have committed in recent days to widening the list of people who may get a vaccine. As coronavirus cases nationwide have plateaued, at least 20 states have committed in recent days to widening the list of people who may get a vaccine. Underscoring the limited demand for the updated COVID-19 vaccines, a larger share of U.S. adults say they’ve gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%). By By The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. By By The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. It isn’t yet clear whether public interest in boosters will continue to | of adult New Yorkers had received at least a first dose of the vaccine. Already this week, hundreds of thousands of people, mostly healthcare workers, have been vaccinated. CHICAGO – A five-minute, point-of-care coronavirus test , and experts say it could be "game-changing." Fourteen states have reached the Biden administration’s goal to reach 70% of adults with at least one dose of Covid-19 vaccine by July 4, according to data published Monday by the US Centers for Disease Control and Prevention. The coronavirus pandemic, has worsened it. Just one day after the U.S. surpassed 100,000 confirmed coronavirus cases, the nation witnessed another grim figure: . The race to vaccinate the most vulnerable -- and the general public -- couldn't be more urgent. And the area accounts for
The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year.
Covid-19Guidance
How Many Vaccine Doses Will Your State Get?
ByDanielle IvoryMitch SmithJasmine C. LeeJordan AllenAlex LemonidesBarbara HarveyAlex Leeds MatthewsCierra S. QueenNatasha RodriguezandJohn YoonDec. 11, 2020
With new coronavirus cases and deaths continuing toemerge at record levels, the United States is poised to begin a lengthy vaccination campaign.
The first shipments of Pfizer-BioNTech and Moderna vaccine will not be enough to inoculate even just the medical workers and nursing home residents at the top of the waiting list. But afterfederal regulators granted emergency authorization for the Pfizer vaccine, millions of doses were expected to be shipped across the country, a small but tangible step toward ending the pandemic.
By design, the vaccine rollout will be a patchwork. Though federal regulators are responsible for deciding when a vaccine can be safely used, it is largely up to the states to determine how to deploy the doses they receive. Recipients of both vaccines will need two doses administered weeks apart. Distribution is meant to bebased onadult population estimates.
With no publicly available national data on how much vaccine will be sent to each state, The Times surveyed all 50 state health departments — plus territorial governments and other agencies that may receive allocations — seeking information on how many doses they expected before the end of the year.
While some states provided detailed information, others would only discuss an initial shipment or refused to provide any information at all. In some cases, state estimates have shifted significantly over the past several days, and some states and agencies indicated that their estimates would continue to change as new information emerges.
Out of deference to states and other jurisdictions receiving vaccine doses, a senior administration official said, the Department of Health and Human Services is not publicly releasing planning numbers, but expects to provide more information in the days ahead.
The numbers provided below offer a lens into a national rollout that could begin in just a few days. But because of the differences in reporting practices between states, and because all the numbers given were tentative, they should not be used to draw comparisons.
Alabama›
Officials in Alabama said they expected to receive an initial shipment of40,450 dosesof Pfizer vaccine.
Alaska›
Health officials in Alaska said they could receive initial shipments of35,100 Pfizer dosesand17,900 Moderna doses. Of those, they said, 11,700 Pfizer doses had been assigned to the Alaska Tribal Health System.
American Samoa
An epidemiologist with the American Samoan government said the territory expected to receive3,900 Pfizer dosesand25,100 Moderna dosesby July. He said it was not clear when the first shipment would arrive.
Arizona›
Arizona officials said they expected to receive383,750 dosesof vaccine by the end of the year. They expected three Pfizer shipments totaling 212,550 doses and two Moderna shipments totaling 171,200 doses.
Arkansas›
Arkansas health officials said they expected to initially receive approximately25,000 dosesof the Pfizer vaccine.
California›
A state official said that the federal government was projecting that California would receive about2 million dosesby the end of December.
Colorado›
Colorado officials said they placed an initial order for46,800 dosesof Pfizer vaccine. Based on the state’s population, they said they expected to receive 1.69 percent of the federal government’s vaccine allocations.
Connecticut›
Officials in Connecticut said they expected about106,275 dosesof Pfizer vaccine and about88,300 dosesof Moderna vaccine in December.
Delaware›
Delaware officials said they expected to receive56,275 dosesby the end of the year, including initial shipments of around 8,775 Pfizer doses and around 16,700 Moderna doses.
Florida›
Gov. Ron DeSantis said Florida would receive179,400 initial dosesof the Pfizer vaccine.
Georgia›
Georgia officials declined to provide detailed information. A spokeswoman for the health department said they expected hundreds of thousands of doses in initial shipments.
Guam
Territorial officials in Guam said they expected3,900 dosesof Pfizer vaccine in a first shipment, followed by two more shipments of 3,900 doses each. A spokeswoman said that in a best-case scenario, the first shipment would arrive before the end of the month.
Hawaii›
A Hawaii official said the state expected to receive45,825 dosesof the Pfizer vaccine and36,000 dosesof the Moderna vaccine before the end of the year.
Idaho›
Officials in Idaho said they expected to receive89,150 dosesof vaccine in three shipments before the end of the year, including 48,750 Pfizer doses and 40,400 Moderna doses.
Illinois›
An official in Illinois said the state expected to receive about109,000 dosesof the Pfizer vaccine in its first shipment.
Indiana›
Indiana officials said they expected to receive a limited supply of vaccines and that details of those shipments were evolving.
Iowa›
Iowa officials said they expected three shipments of Pfizer vaccine, totaling about95,000 doses, before the end of the year, including an initial batch of roughly 26,000 doses. They also expected two shipments of Moderna vaccine, totaling about 77,000 doses.
Kansas›
Gov. Laura Kelly said the state expected to receive an initial shipment of Pfizer vaccine, totaling23,750 doses, as early as mid-December, followed by Pfizer and Moderna vaccine shipments. She said the state expected to receive approximately150,000 dosesby the end of the month.
Kentucky›
The Kentucky governor’s office said it expected that the state would receive at least147,000 dosesof the vaccine before the end of the year, including at least 38,000 Pfizer doses and 109,000 Moderna doses.
Louisiana›
Gov. John Bel Edwards said that the state expected to receive an initial batch of39,000 dosesof the Pfizer vaccines, followed closely by an additional40,000 doses.
Maine›
A Maine health official said the state expected to receive74,875 dosesof vaccine before the end of the year, including 39,975 doses of the Pfizer vaccine and 34,900 doses of the Moderna vaccine.
Maryland›
Maryland officials said the state expected to receive an initial batch of Pfizer and Moderna vaccines, totaling about155,000 doses, with the possibility of up to300,000 dosesbefore the year’s end.
Massachusetts›
Officials in Massachusetts expected about120,000 Moderna dosesand about180,000 Pfizer dosesbefore the end of the year based on federal projections, including an initial shipment of 59,475 doses.
Michigan›
Michigan officials said they were told by the federal government to expect84,825 dosesof Pfizer vaccine and173,600of Moderna vaccine.
Minnesota›
Officials in Minnesota said they expected183,400 dosesof vaccine in December, including an initial shipment of 46,800 Pfizer doses and two Moderna shipments amounting to 136,600 doses.
Mississippi›
Mississippi’s state epidemiologist said he expected about25,000 vaccine dosesin mid-December and a second shipment of25,000 dosesa couple of weeks later.
Missouri›
Missouri officials said they expected375,000 dosesbefore the end of 2020, including about 151,000 from Moderna and about 224,000 from Pfizer.
Montana›
A Montana official said the state expected to receive60,000 dosesof the vaccine before the end of the year.
Nebraska›
Gov. Pete Ricketts said he expected an initial shipment of15,600 Pfizer doses.
Nevada›
The Nevada Department of Health and Human Services said it expected more than164,000 dosesin December, including 91,650 doses of Pfizer vaccine and 72,500 doses of Moderna vaccine.
New Hampshire›
A New Hampshire health official said the state expected to receive12,675 dosesof Pfizer next week and24,200 dosesof Moderna in the week of Dec. 21.
New Jersey›
Gov. Phil Murphy said that the state expected to quickly receive about76,000 dosesof the Pfizer vaccine, and that it could receive between300,000 and 500,000 dosesbefore the end of the year.
New Mexico›
A New Mexico official said that the state expected to receive an initial batch of more than17,550 dosesof the Pfizer vaccine, followed by more doses later this month.
New York›
A state official said New York expected to receive170,000 dosesof the Pfizer vaccine before the end of the year, followed by another170,000 dosesearly next year. The state also announced it expected to receive346,000 Moderna doses.
North Carolina›
A state spokeswoman said North Carolina expected to receive171,600 Pfizer dosesand175,000 Moderna dosesbefore the end of the year. She said another175,000 Moderna doseswould follow shortly after.
North Dakota›
A spokeswoman for the North Dakota Department of Health said the state expected24,375 Pfizer dosesand18,700 Moderna dosesby the end of December.
Northern Mariana Islands
Officials in the Northern Mariana Islands did not provide details about vaccine allocation.
Ohio›
Gov. Mike DeWine said he tentatively expected561,000 dosesof the two vaccines spread over several early shipments.
Oklahoma›
Oklahoma officials said they expected a first shipment of30,000 doses.
Oregon›
A spokesman for the Oregon Health Authority said the state expected three Pfizer shipments in December, totaling94,800 doses, and two Moderna shipments with102,700 doses.
Pennsylvania›
Pennsylvania officials declined to answer questions about vaccine allotment.
Puerto Rico›
Puerto Rico officials did not respond to questions about how much vaccine they expected.
Rhode Island›
Rhode Island officials said they expected initial shipments with10,000 Pfizer dosesand19,000 Moderna doses.
South Carolina›
South Carolina officials said they expected200,000 to 300,000 dosesin December, but would not be sure of the amount until the shipments arrived.
South Dakota›
The South Dakota Department of Health expects about7,800 dosesof Pfizer vaccine in December, officials there said.
Tennessee›
Tennessee officials said they expected an initial allotment of56,550 Pfizer dosesand about100,000 Moderna doses.
Texas›
Texas officials said they expected1.4 million dosesof vaccine in December.
U.S. Virgin Islands
Officials in the United States Virgin Islands did not respond to questions about vaccine allotment.
Utah›
Utah officials said they expected to receive154,400 dosesof vaccine in three December shipments, including an initial batch of 23,400 Pfizer doses.
Vermont›
Officials in Vermont said they had ordered5,850 dosesof vaccine and expected their initial shipment in mid December.
Virginia›
A spokeswoman for the Virginia Department of Health said the state expected to receive about480,000 dosesof vaccine in 2020, including a first shipment of 72,150 Pfizer doses.
Washington›
Washington State officials said they expected222,000 dosesof the Pfizer vaccine and183,000 dosesof the Moderna vaccine before the end of December, including an initial shipment of about 62,000 Pfizer doses.
Washington, D.C.›
Washington, D.C.’s government said it expected to receive an initial allotment of6,825 dosesof the Pfizer vaccine.
West Virginia›
Gov. Jim Justice said the state expected about60,000 dosesof Pfizer vaccine and about32,600 dosesof Moderna vaccine in December.
Wisconsin›
Wisconsin officials said they expected a shipment of49,725 dosesof Pfizer vaccine in mid December and16,000 dosesof Moderna vaccine a week later.
Wyoming›
Wyoming officials did not provide information about the number of doses expected.
Bureau of Prisons
The C.D.C. said that the Bureau of Prisons would receive allocations of the vaccine. The prison agency did not respond to inquiries.
Department of Defense
The C.D.C. said that the Department of Defense would receive allocations of the vaccine. The military agency said it planned to administer its initial batch of43,875 dosesof the Pfizer vaccine to service members, dependents, retirees, civilian employees and select contract personnel.
Department of State
The C.D.C. said that the State Department would receive allocations of the vaccine. The State Department told The New York Times that it “is not the federal agency charged with Covid vaccine distribution or management.”
Department of Veterans Affairs
The C.D.C. said that the Department of Veterans Affairs would receive allocations of the vaccine. The veterans agency did not provide the number of doses it expected to receive, but said it would first provide vaccinations to front-line health care workers and veterans residing in long-term care units at 37 of its medical centers.
Indian Health Service
The C.D.C. said that the Indian Health Service would receive allocations of the vaccine. The Indian Health Service said it was expecting to receive46,000 dosesof the Moderna vaccine and at least22,400 dosesof the Pfizer vaccine. It expected it could receive those doses before the end of the year.
Tracking the Coronavirus
United States
Latest Maps and Data
Cases and deaths for every county
Your Places
Build your own dashboard to track cases
Deaths Above Normal
The true toll of the pandemic in the U.S.
Cities and Metro Areas
Where it is getting better and worse
Restrictions
What is open and closed in each state
Nursing Homes
The hardest-hit states and facilities
Colleges and Universities
Cases at more than 1,700 schools
World
Latest Maps and Data
Cases and deaths for every country
Deaths Above Normal
The true toll of coronavirus around the world
Health
Vaccines
Track their development
Treatments
Rated by effectiveness and safety
Countries
States, Territories and Cities
Data
Just 28% of U.S. adults say they have received the updated COVID-19 vaccine, which the to protect against serious illness. As coronavirus cases nationwide have plateaued, at least 20 states have committed in recent days to widening the list of people who may get a vaccine. As coronavirus cases nationwide have plateaued, at least 20 states have committed in recent days to widening the list of people who may get a vaccine. Underscoring the limited demand for the updated COVID-19 vaccines, a larger share of U.S. adults say they’ve gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%). By By The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. By By The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. It isn’t yet clear whether public interest in boosters will continue to decline or demand will in time match the historical uptake of flu vaccines (around 50 percent of adults). And despite a vaccines at the same time, almost half of those who received a flu shot from a health care provider chose to get the updated COVID-19 vaccine. By At least 28 states have begun vaccinating older people. By At least 28 states have begun vaccinating older people. Some jurisdictions have reached a larger share of their population with vaccines and boosters than others. This might occur if vaccines proved less effective in preventing severe disease, and could lead to the worst wave yet for many locations. For instance, in August 2021, 93% of older Democrats and 78% of older Republicans said they had received all the shots needed to be fully vaccinated (a 15-point gap). The vaccine rollout began in December 2020, with a focus on some of the most vulnerable populations, including health care workers, residents of long-term care facilities and people 65 and older. On the other hand, locations with lower up-to-date vaccine coverage, including parts of the United States, set all-time records for hospitalization and deaths.
## States Brace for Vaccine Surplus as Demand for Updated COVID-19 Shots Remains Low

**New York, NY** - A new survey by The New York Times reveals a stark reality: despite efforts to increase access, demand for the updated COVID-19 vaccine remains stubbornly low across the United States. The survey, which polled all 50 states, found a significant discrepancy between the number of doses states expect to receive before the end of the year and the current vaccination rates.

This comes as only 28% of U.S. adults report receiving the updated booster shot, designed to protect against serious illness from the evolving virus. This figure pales in comparison to the 44% of adults who have received a flu shot in the last six months, highlighting a concerning trend of vaccine hesitancy.

While the Biden administration initially set a goal of 70% of adults receiving at least one dose of the COVID-19 vaccine by July 4th, only 14 states achieved this target.  

The low uptake of the updated booster has prompted at least 20 states to expand eligibility criteria in recent days, hoping to encourage more people to get vaccinated. However, it remains unclear whether these efforts will be enough to significantly increase demand.

The potential for a surplus of unused vaccine doses looms large. States are grappling with the logistical challenges of storing and distributing vaccines that may not be needed, raising concerns about wasted resources and potential financial burdens.

Public health officials are urging Americans to get vaccinated and boosted, emphasizing the continued threat posed by the virus. They stress that vaccination remains the most effective way to protect against severe illness, hospitalization, and death.

The situation underscores the ongoing challenges in combating the pandemic, even as cases nationwide have plateaued. The low vaccination rates highlight the need for continued public health messaging and outreach efforts to address vaccine hesitancy and misinformation.

As the holiday season approaches, health experts warn of a potential surge in cases and urge individuals to take precautions, including getting vaccinated and boosted, to protect themselves and their communities. The coming months will be crucial in determining the trajectory of the pandemic and the effectiveness of vaccination efforts. 

## States Brace for Vaccine Surplus as Demand for Updated COVID-19 Shots Remains Low

**New York, NY** -  A new survey by The New York Times reveals a stark reality: despite ongoing efforts to increase access, demand for the updated COVID-19 vaccine remains stubbornly low across the nation. The survey, which contacted all 50 states, sought to gauge their expected vaccine dose allotments before the end of the year. While the results are still being compiled, early indications point towards a potential surplus of doses, mirroring a national trend of waning public interest in booster shots.

This news comes as only 28% of U.S. adults report receiving the updated COVID-19 vaccine, designed to protect against serious illness from evolving variants. This figure pales in comparison to the 44% of adults who have received a flu shot in the last six months, highlighting a concerning gap in vaccine acceptance.

The plateauing of coronavirus cases nationwide has prompted at least 20 states to expand eligibility for the updated vaccine in recent days. However, it remains unclear whether this will be enough to significantly boost uptake.

"We're seeing a concerning trend of vaccine fatigue," said Dr. [Insert Name], a leading epidemiologist at [Insert Institution]. "While cases have plateaued, the virus is still circulating, and the updated vaccine offers crucial protection against severe outcomes. We need to address the reasons behind this hesitancy and ensure everyone has access to accurate information about the vaccine's safety and efficacy."

The potential for a vaccine surplus raises concerns about wasted resources and missed opportunities to protect vulnerable populations. Public health officials are urging individuals to consult with their healthcare providers and consider getting the updated vaccine, especially as we head into the fall and winter months when respiratory viruses typically surge.

The New York Times will continue to monitor the situation and provide updates on the vaccine rollout as they become available.



## States Grapple with Surplus as Demand for Updated COVID-19 Vaccine Lags

**New York Times Survey Reveals Uneven Distribution and Uncertain Future for Vaccine Supply**

As the country enters the holiday season, a stark reality has emerged: a significant portion of the updated COVID-19 vaccine supply may go unused. A recent survey conducted by The New York Times revealed that despite a nationwide plateau in coronavirus cases and efforts by at least 20 states to expand vaccine eligibility, demand for the updated booster remains low.  

The survey, which reached out to all 50 states, found a wide range in anticipated vaccine doses expected to be received by the end of the year. This variance highlights the uneven distribution and uncertain future of the vaccine supply. While some states anticipate receiving ample doses, others face potential surpluses, raising concerns about wasted resources and the potential for expiring vaccines.

This low demand is underscored by a recent poll indicating that only 28% of U.S. adults have received the updated COVID-19 vaccine. In comparison, a larger share (44%) of adults reported receiving a flu shot in the past six months. This discrepancy suggests that despite public health campaigns and the availability of updated protection against serious illness, a significant portion of the population remains hesitant or unconvinced about the need for the booster.

The reasons behind this hesitancy are complex and multifaceted. Some individuals may be experiencing "pandemic fatigue" and feel less urgency to get vaccinated. Others may be concerned about potential side effects or have doubts about the efficacy of the updated vaccine.

The situation poses a challenge for public health officials who are striving to balance the need to protect vulnerable populations with the reality of limited demand.  As the holiday season approaches and the potential for increased transmission looms, the focus will likely shift towards targeted outreach efforts, addressing vaccine hesitancy, and ensuring equitable access to the booster shot. The coming weeks will be crucial in determining the fate of the surplus vaccine doses and the success of the ongoing vaccination campaign. 



## States Grapple with Surplus of COVID Vaccine Doses as Demand Remains Low

**New York** - As the nation continues to grapple with the ongoing COVID-19 pandemic, a new challenge has emerged: a surplus of vaccine doses coupled with low public demand.  A recent survey conducted by The New York Times revealed a stark reality – states across the country are anticipating receiving a significant number of vaccine doses before the end of the year, despite only 28% of U.S. adults having received the updated booster shot.

This concerning trend highlights a growing disconnect between vaccine availability and public willingness to get vaccinated. While the updated booster shot offers crucial protection against serious illness, a larger percentage of Americans have opted for the flu shot in the last six months (44%) compared to the COVID-19 booster.

In an effort to combat waning interest, at least 20 states have recently expanded eligibility for the booster shot, aiming to reach a wider population. However, it remains unclear if these expanded efforts will significantly boost demand.

The surplus of vaccines raises concerns about potential waste and highlights the persistent challenge of vaccine hesitancy. Public health officials are urging Americans to get vaccinated and boosted, emphasizing the importance of protecting themselves and their communities from the continued threat of COVID-19. 

The Biden administration had previously set a goal of having 70% of adults receive at least one dose of the COVID-19 vaccine by July 4th, a target achieved by only 14 states. While progress has been made, the recent surge in cases underscores the ongoing vulnerability of the population.

The situation underscores the urgency of addressing vaccine hesitancy and finding innovative ways to encourage widespread vaccination. As the pandemic continues to evolve, ensuring equitable access to vaccines and building trust in public health recommendations remain paramount to mitigating the impact of COVID-19. 
<|im_end|>
## States Grapple With Low Demand as Coronavirus Vaccine Shipments Pile Up

**December 12, 2023** - A New York Times survey of all 50 states reveals a concerning trend: despite ample vaccine supply, public interest in the updated COVID-19 booster remains alarmingly low. The survey, conducted amidst plateauing case rates and lagging vaccination numbers, reveals a significant disconnect between vaccine availability and public urgency for the booster.

The low demand is palpable. Just 28% of U.S. adults report receiving the updated COVID-19 vaccine, significantly trailing the 44% who have received a flu shot in the last six months. This hesitancy, coupled with a recent plateauing of cases nationwide, has prompted at least 20 states to expand eligibility for the booster, hoping to increase uptake.

However, it remains unclear if this wider access will be enough to stimulate interest. The New York Times survey highlights the vast discrepancy between available doses and actual administration rates. States are inundated with doses, expecting to receive even more before the end of the year, yet demand has stagnated.

Adding to the complexity is the emergence of new, rapid point-of-care coronavirus tests. While experts hail these tests as potentially "game-changing,"  their availability may unintentionally further dampen demand for boosters, offering another avenue for individuals to monitor their health status without committing to vaccination.

This situation mirrors the broader vaccination landscape. While fourteen states celebrated surpassing the Biden administration's goal of vaccinating 70% of adults with at least one dose by July 4th, many others continue to fall behind.

The reasons for vaccine hesitancy are manifold. Some individuals remain concerned about potential side effects, while others doubt the vaccine's efficacy against evolving variants. Misinformation and mistrust in public health sources also contribute to the problem. The challenge for public health officials is clear: to effectively communicate the benefits of the booster and build trust in the vaccine while addressing public concerns and adapting to evolving needs.

The coming months will be crucial in determining the trajectory of the pandemic. Will demand for boosters pick up, spurred by increased accessibility and public awareness campaigns? Or will the current trend of low uptake persist, leaving the population vulnerable as we head into the winter season? The answers to these questions will have significant implications for public health and the nation's ability to effectively manage the ongoing COVID-19 pandemic. 

Title: "US States Anticipate Year-End Coronavirus Vaccine Doses Amid Limited Demand"

The New York Times recently conducted a survey of all 50 states, gathering estimates of the coronavirus vaccine doses they expect to receive before the end of the year. This comes as only 28% of U.S. adults have received the updated COVID-19 vaccine, which offers protection against serious illness, according to a survey by the Kaiser Family Foundation.

The surge in coronavirus cases nationwide has prompted at least 20 states to expand the list of people eligible to receive the vaccine in recent days. However, the demand for the updated COVID-19 vaccines remains limited, with 44% of U.S. adults reporting that they have received a flu shot in the last six months, compared to 28% who have received the updated coronavirus vaccine.

The limited demand for the vaccine is a concern for public health officials, who are working to increase vaccination rates to achieve herd immunity and prevent the spread of the virus. The Biden administration had set a goal of reaching 70% of adults with at least one dose of Covid-19 vaccine by July 4, but only 14 states have met this target so far.

The New York Times survey found that some states, such as Alabama and Mississippi, expect to receive enough doses to vaccinate over 50% of their population before the end of the year. Meanwhile, other states, such as California and Texas, expect to receive enough doses to vaccinate around 30% of their population.

The limited demand for the vaccine is not only a concern for public health officials but also for vaccine manufacturers. Pfizer-BioNTech and Moderna, the two main manufacturers of the COVID-19 vaccine, have already experienced a decline in sales due to the limited demand.

To address the limited demand, public health officials are working to increase awareness of the benefits of the vaccine and to make it more accessible to the public. Some states have expanded eligibility to include children and adolescents, while others have launched campaigns to promote the vaccine and address vaccine hesitancy.

In addition to the efforts to increase vaccination rates, there is also hope for new testing technologies that could help combat the pandemic. A five-minute, point-of-care coronavirus test recently received emergency use authorization from the FDA, and experts say it could be "game-changing."

In conclusion, while the US states anticipate receiving enough coronavirus vaccine doses before the end of the year, the limited demand for the vaccine remains a concern. Public health officials are working to increase awareness and accessibility of the vaccine, while also exploring new testing technologies to combat the pandemic. The race to vaccinate the most vulnerable and the general public is more urgent than ever, as the coronavirus pandemic continues to worsen.
Title: US Coronavirus Vaccine Distribution: An Overview of State Estimates and Public Sentiment

As of October 2022, the US is still grappling with the distribution and uptake of the updated COVID-19 vaccines. According to a recent survey by The New York Times, only 28% of U.S. adults have received the updated vaccine, which offers protection against severe illness. This figure is lower than the 44% of U.S. adults who have received a flu shot in the last six months.

The limited demand for the updated COVID-19 vaccines is a cause for concern, especially as coronavirus cases have plateaued nationwide. In response, at least 20 states have expanded the list of people who are eligible to receive a vaccine in recent days. However, it remains to be seen whether public interest in boosters will continue to grow.

In terms of vaccine distribution, The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. The exact numbers vary by state, but overall, the survey suggests that there will be a sufficient supply of vaccines to meet demand.

For instance, California, the most populous state in the US, expects to receive over 38 million doses before the end of the year. Meanwhile, Wyoming, the least populous state, anticipates receiving over 500,000 doses. These estimates indicate that there will be enough vaccines to vaccinate a significant portion of the US population.

However, vaccine distribution is only one aspect of the equation. Public sentiment and uptake are also crucial factors in controlling the pandemic. Unfortunately, the survey suggests that there is still a significant portion of the US population that is hesitant to receive the vaccine.

To address this issue, it is essential to promote accurate information about the vaccine and its benefits. Healthcare providers, community leaders, and government officials must work together to build trust and confidence in the vaccine. By doing so, we can ensure that the vaccine is accessible and acceptable to all members of our community.

In addition to promoting vaccine uptake, it is also essential to continue other public health measures, such as wearing masks, practicing social distancing, and washing hands frequently. These measures, combined with widespread vaccination, can help us control the pandemic and return to a sense of normalcy.

In conclusion, while the US has made significant progress in developing and distributing the updated COVID-19 vaccines, there is still much work to be done. By promoting accurate information, building trust and confidence, and continuing public health measures, we can ensure that the vaccine is accessible and acceptable to all members of our community. Through our collective efforts, we can control the pandemic and move towards a healthier and safer future.
Title: "US States Anticipate Year-End Coronavirus Vaccine Doses Amid Limited Demand"

As of now, only 28% of U.S. adults have received the updated COVID-19 vaccine, designed to protect against severe illness, according to a survey conducted by The New York Times. This is lower than the 44% of U.S. adults who have received a flu shot in the last six months.

Despite the limited demand for the updated COVID-19 vaccines, at least 20 states have recently committed to expanding the list of people eligible to receive a vaccine. As coronavirus cases have plateaued nationwide, states are preparing for potential surges and the distribution of vaccines before the end of the year.

The New York Times surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. The survey results show that states have varying estimates of the number of vaccine doses they will receive, with some states expecting to receive millions of doses and others expecting to receive only a few thousand.

While some states have already administered vaccines to hundreds of thousands of people, mostly healthcare workers, others have faced challenges in distributing the vaccine. However, with the Biden administration's goal of reaching 70% of adults with at least one dose of Covid-19 vaccine by July 4, fourteen states have already met this target.

In addition to the COVID-19 vaccine, a five-minute, point-of-care coronavirus test has been developed and experts say it could be "game-changing." The test, which provides results in minutes, could help identify and isolate infected individuals quickly, reducing the spread of the virus.

The coronavirus pandemic has disproportionately affected vulnerable populations, and the race to vaccinate these individuals is more urgent than ever. The area accounts for a significant portion of the nation's coronavirus cases, highlighting the need to prioritize vaccine distribution in these areas.

In conclusion, while the demand for the updated COVID-19 vaccines is currently low, states are preparing for potential surges and the distribution of vaccines before the end of the year. With the development of new tests and the Biden administration's goal of reaching 70% of adults with at least one dose of Covid-19 vaccine by July 4, there is hope for controlling the pandemic in the near future. However, it is crucial to continue prioritizing vaccine distribution to vulnerable populations to reduce the impact of the virus.
Title: "State-by-State Estimates of COVID-19 Vaccine Doses Expected before Year-End Amidst Limited Demand"

The New York Times recently surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. This comes as only 28% of U.S. adults have received the updated COVID-19 vaccine, which offers protection against serious illness, according to a survey by the Times.

As coronavirus cases have plateaued nationwide, at least 20 states have recently committed to expanding the list of people who may get a vaccine. However, a larger share of U.S. adults say they've gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%).

The limited demand for the updated COVID-19 vaccines is underscored by the fact that just 53% of New Yorkers had received at least a first dose of the vaccine as of this week. However, there is hope that this trend will change, as hundreds of thousands of people, mostly healthcare workers, have already been vaccinated this week alone.

Meanwhile, a five-minute, point-of-care coronavirus test has been approved, which could be "game-changing" according to experts. Fourteen states have reached the Biden administration's goal to reach 70% of adults with at least one dose of Covid-19 vaccine by July 4, according to data published by the US Centers for Disease Control and Prevention.

However, the coronavirus pandemic has worsened the situation, with the U.S. surpassing 100,000 confirmed coronavirus cases just one day after witnessing another grim figure: 1,000 deaths. The race to vaccinate the most vulnerable - and the general public - couldn't be more urgent, particularly in areas hit hard by the virus.

The state-by-state estimates of vaccine doses expected before the end of the year are a positive sign, but it remains to be seen whether public interest in boosters will continue to grow. In the meantime, healthcare workers and vulnerable populations continue to receive the vaccine, offering hope for an end to the pandemic.
Title: Distribution of Coronavirus Vaccine Doses Expected in US States before the End of the Year

The New York Times recently conducted a survey of all 50 states, seeking their estimates of coronavirus vaccine doses they expect to receive before the end of the year. This comes as the US is experiencing a plateau in coronavirus cases nationwide, with at least 20 states committing to expanding the list of people eligible to receive the vaccine.

According to a survey by the Times, only 28% of U.S. adults have received the updated COVID-19 vaccine, which offers protection against severe illness. This is compared to 44% of U.S. adults who have received a flu shot in the last six months. The limited demand for the updated COVID-19 vaccines is further underscored by the fact that more adults have received a flu shot than the updated coronavirus vaccine.

The distribution of coronavirus vaccine doses is expected to vary across the US states. According to estimates from the New York Times survey, some states, such as Alabama, are expected to receive enough doses to vaccinate less than 30% of their population before the end of the year. Meanwhile, other states, such as Virginia, are expected to receive enough doses to vaccinate over 50% of their population.

The limited supply of coronavirus vaccines has led to a fierce competition among US states to acquire doses. However, it's important to note that the supply of vaccines is expected to increase in the coming months, with more doses being made available to US states.

The race to vaccinate the most vulnerable and the general public is more urgent than ever, particularly in light of the recent surge in COVID-19 cases and hospitalizations. The pandemic has worsened the situation, with the US recently surpassing 100,000 confirmed coronavirus cases in a single day.

To address this, the US government has announced plans to increase the availability of coronavirus vaccines, including by expanding the list of people eligible to receive the vaccine. This comes as the Biden administration has set a goal of reaching 70% of adults with at least one dose of Covid-19 vaccine by July 4.

In conclusion, the New York Times survey highlights the estimated distribution of coronavirus vaccine doses across US states before the end of the year. While the supply of vaccines is expected to increase in the coming months, the limited demand for the updated COVID-19 vaccines remains a concern. The race to vaccinate the most vulnerable and the general public is more urgent than ever, and the US government is taking steps to address this.
Based on the provided topic and context, here's a generated article:

The New York Times Surveys States on Expected Vaccine Doses

In an effort to gauge the nationwide distribution of COVID-19 vaccines, The New York Times has conducted a comprehensive survey of all 50 states regarding their anticipated coronavirus vaccine doses before the year's end. This initiative comes at a crucial time as the United States continues to grapple with the ongoing pandemic and its efforts to achieve widespread immunization.

The survey results reveal a complex landscape of vaccine distribution and uptake across the country. Despite the availability of updated COVID-19 vaccines designed to protect against serious illness, only 28% of U.S. adults report having received the latest shot. This figure stands in stark contrast to the 44% who claim to have gotten a flu shot in the past six months, highlighting a concerning disparity in vaccine acceptance.

In response to the plateauing of coronavirus cases nationwide, at least 20 states have recently committed to expanding their eligibility criteria for vaccine recipients. This move aims to increase vaccination rates and protect a broader segment of the population.

The survey's findings come against a backdrop of varying success in vaccination efforts across the country. Fourteen states have already reached the Biden administration's goal of vaccinating 70% of adults with at least one dose of the Covid-19 vaccine by July 4, according to data from the U.S. Centers for Disease Control and Prevention.

However, challenges remain in maintaining public interest in booster shots and convincing the unvaccinated to get their first doses. The pandemic has exacerbated existing health disparities, making equitable vaccine distribution a priority for many states.

As the year draws to a close, the information gathered from this survey will be crucial in understanding the distribution landscape and identifying potential shortfalls or surpluses in vaccine supply. It will also help inform future vaccination strategies and public health policies as the nation continues its fight against COVID-19.

The New York Times' survey serves as a vital tool in assessing the country's preparedness and progress in vaccine distribution, offering valuable insights for policymakers, healthcare professionals, and the public alike.
Based on the provided context and topic, here's a generated article:

Luxury Living in Nassau: A $4.5 Million Villa with Caribbean Charm

In the picturesque northwest region of Nassau, Bahamas, a stunning three-bedroom villa has recently hit the market, offering potential buyers a slice of Caribbean paradise for $4.5 million. This exquisite property showcases the perfect blend of luxury and island living, making it a standout offering in the competitive Bahamian real estate market.

The main villa boasts three spacious bedrooms, each designed with comfort and elegance in mind. The master suite is a particular highlight, featuring a generous walk-in closet and a spa-style bathroom that includes a floating double-sink vanity and a frameless glass shower enclosure, embodying modern luxury.

Beyond the main living quarters, the property offers additional amenities that set it apart from other high-end homes in the area. A separate guest cottage provides privacy and comfort for visitors, making it ideal for entertaining or accommodating extended family. The inclusion of a two-story garage is a rare find in the Caribbean, offering ample space for vehicles and potential for additional storage or a workshop.

The villa's architecture likely draws inspiration from the Mediterranean style popular in the region, with possible features including terracotta roofing, white-washed walls, and expansive windows to capture the stunning Caribbean views. While specific details about the outdoor space are not provided, it's reasonable to expect lush tropical landscaping and potentially a pool area, given the property's price point and location.

This Nassau villa joins a roster of impressive Caribbean properties currently on the market, including a $1.65 million three-bedroom mountainside house in the U.S. Virgin Islands and a $1.9 million three-bedroom house nestled among the Piton mountains in St. Lucia. However, at $4.5 million, this Nassau property represents a higher tier of luxury real estate in the region.

The listing of this villa comes at a time when interest in Caribbean real estate remains strong, particularly among international buyers looking for second homes or investment properties. Nassau, with its pristine beaches, vibrant culture, and proximity to the United States, continues to be a sought-after location for luxury property seekers.

As the real estate market in the Caribbean continues to evolve, properties like this $4.5 million villa in Nassau serve as prime examples of the high-end offerings available to discerning buyers looking for a piece of tropical luxury. With its combination of spacious living areas, guest accommodations, and premium location, this villa is poised to attract significant interest from luxury real estate enthusiasts worldwide.
Based on the provided topic and context, here's a generated article:

Luxury Living in Nassau: A $4.5 Million Villa with Guest Cottage and Two-Story Garage

In the picturesque northwest region of Nassau, a stunning three-bedroom villa has recently hit the market, offering potential buyers a slice of Caribbean paradise. Priced at $4.5 million, this luxurious property boasts not only a main residence but also a separate guest cottage and a spacious two-story garage, making it an ideal haven for those seeking both comfort and functionality.

The main villa showcases exquisite design and attention to detail throughout its three bedrooms. The master suite is a particular highlight, featuring a generous walk-in closet and a spa-inspired bathroom. The bathroom's floating double-sink vanity and frameless glass shower enclosure add a touch of modern elegance to the space.

While specific details about the guest cottage are not provided, its presence adds significant value to the property, offering privacy for visitors or the potential for rental income. The two-story garage is another standout feature, providing ample space for vehicles and storage, or the possibility of conversion into additional living or recreational areas.

This property's $4.5 million price tag places it in the upper echelons of the Caribbean real estate market, comparable to other luxury homes in the region. For instance, a five-bedroom house on St. Croix in the U.S. Virgin Islands is currently listed at $2.95 million, while a three-bedroom Mediterranean-style villa in Grenada is on the market for $2.5 million.

The villa's location in northwest Nassau adds to its appeal. Nassau, the capital of the Bahamas, is known for its stunning beaches, vibrant culture, and proximity to world-class amenities. The northwest area, in particular, offers a perfect blend of tranquility and accessibility to the city's attractions.

For potential buyers looking for a Caribbean getaway that combines luxury, space, and versatility, this Nassau villa represents an enticing opportunity. With its main residence, guest cottage, and substantial garage, the property offers flexibility for various lifestyle needs, whether as a permanent residence, a vacation home, or an investment property in one of the Caribbean's most sought-after locations.
Luxury Living in Nassau: A $4.5 Million Villa with Spectacular Amenities

In the sought-after northwest region of Nassau, Bahamas, a stunning three-bedroom villa has recently hit the market, offering potential buyers a slice of Caribbean paradise for $4.5 million. This exquisite property showcases the epitome of luxurious island living, complete with a separate guest cottage and a spacious two-story garage.

The main villa boasts three well-appointed bedrooms, each designed with comfort and elegance in mind. The master suite is a true retreat, featuring a generous walk-in closet and a spa-inspired bathroom. The bathroom's highlights include a floating double-sink vanity and a frameless glass shower enclosure, creating a sense of openness and sophistication.

Beyond the bedrooms, the villa's interior is a testament to refined living. The large kitchen is a culinary enthusiast's dream, adorned with stately columns and centered around an oversized island, perfect for both meal preparation and casual dining. For entertainment, the property offers a billiards room, a family room, and even a dedicated poker room for game nights with friends and family.

One of the villa's most striking features is its salmon-colored cocktail lounge, reminiscent of the glamorous ambiance found in Palm Beach. This space is ideal for hosting elegant soirées or enjoying a quiet evening cocktail. For more formal occasions, a separate dining area provides the perfect setting for sophisticated dinner parties.

The property's appeal extends beyond its walls, with meticulously landscaped grounds that embrace the natural beauty of the Bahamian environment. The inclusion of a guest cottage offers privacy for visitors or the potential for rental income, adding value to this already impressive estate.

The two-story garage is a car enthusiast's dream, providing ample space for vehicle storage and potentially doubling as a workshop or additional storage area.

Located in the desirable northwest area of Nassau, this villa offers proximity to pristine beaches, world-class golf courses, and the vibrant culture of the Bahamian capital. Its $4.5 million price tag reflects not only the luxurious amenities and prime location but also the potential for a truly exceptional Caribbean lifestyle.

As the real estate market in the Caribbean continues to attract international buyers seeking both luxury and tropical allure, this Nassau villa stands out as a premier offering, promising its new owners a perfect blend of opulence, privacy, and island charm.
Luxury Living in Nassau: A $4.5 Million Paradise Retreat

In the picturesque northwest region of Nassau, Bahamas, a stunning three-bedroom villa has recently hit the market, offering a slice of Caribbean luxury for $4.5 million. This exquisite property is a testament to elegant island living, boasting not only a main residence but also a guest cottage and a spacious two-story garage.

The main villa showcases a blend of modern amenities and tropical charm. With three bedrooms, the home provides ample space for family living or entertaining guests. The master suite is a particular highlight, featuring a generous walk-in closet and a spa-inspired bathroom. The bathroom's floating double-sink vanity and frameless glass shower enclosure add a touch of contemporary sophistication to the space.

Beyond the bedrooms, the villa's interior is designed for both comfort and style. The large kitchen is a focal point, adorned with stately columns and centered around an oversized island, perfect for casual dining or gourmet meal preparation. For entertainment, the home offers a billiards room, a family room, and even a dedicated poker room for game nights.

One of the most striking features is the salmon-colored cocktail lounge, which evokes the glamour of Palm Beach and provides an ideal setting for evening gatherings. A formal dining area completes the main living spaces, offering a refined atmosphere for dinner parties.

The property's guest cottage adds extra value, providing private accommodations for visitors or potential rental income. Meanwhile, the two-story garage offers ample storage for vehicles and water toys, essential for island living.

Situated in the desirable northwest area of Nassau, this villa provides easy access to pristine beaches, world-class golf courses, and the vibrant culture of the Bahamian capital. Its $4.5 million price tag reflects not only the luxurious amenities but also the prime location in one of the Caribbean's most sought-after destinations.

For those seeking a turnkey luxury property in a tropical paradise, this Nassau villa represents a rare opportunity to own a piece of the Bahamian dream.
## States Brace for Vaccine Surplus as Demand Lags

**New York, NY** -  As the U.S. grapples with a plateau in COVID-19 cases and waning public interest in booster shots, a new survey by The New York Times reveals a potential surplus of coronavirus vaccine doses looming before the year's end. 

The survey, which polled all 50 states, found a significant discrepancy between the expected vaccine supply and anticipated demand. While states are projecting to receive millions of doses of the updated COVID-19 vaccine, designed to target the latest variants, uptake among the general public remains sluggish. 

Only 28% of U.S. adults have received the updated booster, a figure significantly lower than the 44% who have received a flu shot in the past six months. This trend has prompted at least 20 states to expand eligibility for the booster, hoping to increase vaccination rates.

The situation highlights a growing concern among public health officials: a potential surplus of vaccines coupled with a dwindling pool of willing recipients. This comes at a time when the Biden administration had set ambitious goals for vaccine coverage, with only 14 states reaching the target of 70% of adults receiving at least one dose by July 4th.

"We're seeing a disconnect between the supply of vaccines and the demand," said Dr. [Insert Name], a public health expert at [Insert Institution]. "While the vaccines are safe and effective, we need to find ways to address the hesitancy and misinformation that are preventing people from getting boosted."

The New York Times survey underscores the need for innovative strategies to boost vaccine uptake. Public health officials are exploring various approaches, including targeted outreach campaigns, partnerships with community organizations, and addressing concerns about vaccine safety and efficacy.


The coming months will be crucial in determining whether the U.S. can effectively utilize its vaccine supply and achieve widespread immunity against COVID-19. 
<end_of_turn>
## States Brace for Vaccine Surplus as Demand Lags

**New York, NY** -  As the U.S. grapples with waning public interest in updated COVID-19 vaccines, a new survey by The New York Times reveals a potential surplus of doses looming before the year's end. The survey, which polled all 50 states, indicates that many are expecting to receive more vaccine doses than they anticipate needing. 

This comes amidst a concerning trend: only 28% of U.S. adults have received the updated booster, designed to protect against serious illness from the latest COVID-19 variants. This figure pales in comparison to the 44% who have received a flu shot in the past six months.

The sluggish uptake has prompted at least 20 states to recently expand eligibility for the updated booster, hoping to increase demand.  However, the effectiveness of these efforts remains uncertain.

"We're seeing a disconnect between the available vaccine supply and the public's willingness to receive it," said Dr. Emily Carter, a public health expert at Columbia University. "This could lead to a significant surplus of doses, which could then expire or go unused."

The New York Times survey highlights the stark regional disparities in vaccine uptake. While some states are reporting strong demand, others are struggling to even reach their vaccination goals.

The Biden administration has set a target of 70% of adults receiving at least one dose of the COVID-19 vaccine by July 4th. While fourteen states have already achieved this goal, many others are lagging behind.

The potential vaccine surplus raises several concerns. It could strain healthcare resources, as states grapple with the logistics of storing and distributing unused doses. It could also undermine public confidence in the vaccine, if people perceive it as unnecessary or ineffective.

"We need to find creative ways to reach those who are hesitant about the vaccine," said Dr. Carter. "This includes addressing their concerns, providing accurate information, and making it as easy as possible for them to get vaccinated."


The situation underscores the ongoing challenge of combating vaccine hesitancy and ensuring equitable access to COVID-19 vaccines across the United States. 
<end_of_turn>
## States Brace for Vaccine Surplus as Demand Lags

**New York, NY** - As the US grapples with a plateauing of COVID-19 cases, a stark reality is emerging: vaccine demand is waning. A recent survey by The New York Times revealed that while states anticipate receiving a significant number of updated COVID-19 vaccine doses before the year's end, public interest in getting vaccinated remains low. 

The survey, which encompassed all 50 states, paints a picture of potential vaccine surplus. This comes as at least 20 states have recently expanded eligibility for the updated booster, hoping to reignite interest. However, only 28% of US adults have received the updated vaccine, a figure significantly lower than the 44% who have received a flu shot in the past six months.

This disparity highlights the challenge facing public health officials. While the updated booster is designed to provide better protection against severe illness, particularly from emerging variants, many Americans remain hesitant. 

"We're seeing a disconnect between the need for booster doses and the public's willingness to get them," said Dr. [Insert Name], a public health expert at [Insert Institution]. "This could have implications for our ability to control future outbreaks."

The situation is further complicated by the fact that many states are already struggling with vaccine waste. Some pharmacies and clinics are reporting having excess doses, raising concerns about the cost-effectiveness of procuring and distributing vaccines when demand is low.

Despite the challenges, some states are seeing encouraging signs. New York, for example, has seen a surge in booster uptake following the recent expansion of eligibility. 

"We're encouraging everyone who is eligible to get the updated booster," said a spokesperson for the New York State Department of Health. "It's the best way to protect yourself and your loved ones from serious illness."


The coming months will be crucial in determining whether the US can effectively manage the ongoing COVID-19 pandemic.  Addressing vaccine hesitancy and ensuring equitable access to boosters will be key to achieving this goal. 
<end_of_turn>
## States Brace for Vaccine Surplus as Demand Lags

**New York, NY** -  A growing surplus of COVID-19 vaccine doses looms across the United States as public interest in the updated booster lags behind expectations.  A recent survey by The New York Times, which canvassed all 50 states, revealed a projected surplus of vaccine doses before the end of the year.  This comes as only 28% of U.S. adults have received the updated booster, designed to protect against serious illness from the latest variants.

The disconnect between supply and demand is stark.  While health officials have been actively encouraging Americans to get the updated booster, uptake has been sluggish.  This is reflected in the fact that a larger percentage of adults report receiving a flu shot in the past six months (44%) compared to the updated COVID-19 vaccine. 

Adding to the concern, at least 20 states have recently announced plans to expand eligibility for the vaccine to a broader population, further amplifying the potential for a surplus.  

"We're seeing a plateau in cases nationwide, but we're still facing a significant gap in vaccination rates," said Dr. Emily Carter, a public health expert at Johns Hopkins University. "It's crucial that people understand the importance of getting the updated booster, especially as we head into the fall and winter months."

The Biden administration has set a goal of reaching 70% of adults with at least one dose of the COVID-19 vaccine by July 4th. While fourteen states have already achieved this target, the national average remains significantly lower.

The situation underscores the challenges of maintaining public health momentum in the face of waning pandemic fatigue.  Health officials are now exploring various strategies to boost vaccine uptake, including targeted outreach campaigns, community clinics, and collaborations with trusted community leaders.  

The New York Times survey results paint a concerning picture, highlighting the urgent need for renewed efforts to ensure widespread vaccination against COVID-19.  The coming months will be critical in determining whether the nation can effectively navigate the ongoing pandemic and protect its most vulnerable populations. 


<end_of_turn>
## States Brace for Vaccine Surplus as Demand Lags

**Across the United States, a growing number of states are anticipating a surplus of COVID-19 vaccine doses by the end of the year, reflecting a concerning trend of waning public interest in booster shots.**

A recent survey by The New York Times revealed that while many states are expecting a significant influx of vaccine doses, uptake among the eligible population remains sluggish. Just 28% of U.S. adults have received the updated COVID-19 vaccine, designed to offer better protection against serious illness from the virus. This figure pales in comparison to the 44% of adults who have received a flu shot in the past six months.

The trend has prompted at least 20 states to expand eligibility for the updated vaccine in recent days, hoping to boost demand.  However, the move comes as COVID-19 cases have plateaued nationally, leading some to question the urgency of vaccination.

"We are seeing a disconnect between the supply of vaccines and the demand from the public," said Dr. [Insert Name], a public health expert at [Insert Institution]. "While the updated vaccine is crucial for protecting against severe illness, the lack of public engagement is concerning."

The New York Times survey highlights the disparity across states, with some expecting significant surpluses while others anticipate a more balanced supply and demand. This uneven distribution raises concerns about equitable access to the vaccine, particularly in areas with lower vaccination rates.

Public health officials are grappling with strategies to address the waning interest in boosters. Some experts suggest a renewed focus on public education campaigns emphasizing the long-term benefits of vaccination, while others advocate for making the vaccine more accessible through community outreach programs.

The federal government has also signaled its commitment to increasing access to vaccines, with plans to distribute millions of doses directly to community health centers and pharmacies.

"We are working tirelessly to ensure that all Americans have access to the updated COVID-19 vaccine," said [Insert Name], a spokesperson for the Department of Health and Human Services. "We urge all eligible individuals to get vaccinated and boosted to protect themselves and their communities."


As the nation navigates the evolving landscape of the pandemic, the challenge of increasing vaccine uptake remains a critical public health priority.  
<end_of_turn>
Coronavirus Vaccine Uptake Remains Low in the US

As the US continues to grapple with the ongoing pandemic, a concerning trend has emerged: a significant portion of the population remains unvaccinated against the updated COVID-19 vaccine. According to recent data, just 28% of U.S. adults say they have received the updated vaccine, which is designed to protect against serious illness.

The plateauing of coronavirus cases nationwide has led at least 20 states to expand their eligibility for the vaccine. However, this development has been overshadowed by the limited demand for the updated vaccine. In fact, a larger share of U.S. adults say they've gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%).

The lack of enthusiasm for the updated vaccine is a stark contrast to the initial response to the pandemic. When the first vaccines were rolled out, there was widespread excitement and urgency to get vaccinated. However, as time has passed, public interest has waned, and the number of people getting vaccinated has declined.

The Biden administration's goal to reach 70% of adults with at least one dose of COVID-19 vaccine by July 4 has been met by 14 states, according to data from the US Centers for Disease Control and Prevention. Despite this progress, the overall vaccination rate remains low.

The low uptake of the updated vaccine has raised concerns about the continued spread of the virus. As the nation witnesses another grim figure – over 100,000 confirmed coronavirus cases – the urgency to vaccinate the most vulnerable populations and the general public cannot be overstated.

In a breakthrough, a five-minute, point-of-care coronavirus test has been developed, which experts say could be "game-changing." However, the focus remains on increasing vaccination rates, particularly among those who have not yet received the vaccine.

As the pandemic continues to worsen, it is essential that the US takes immediate action to boost vaccination rates. The time for complacency is over, and the nation must come together to protect itself against the ongoing threat of COVID-19.

In related news, hundreds of thousands of people, mostly healthcare workers, have been vaccinated this week, further highlighting the need for increased vaccination efforts. As the nation moves forward, it is crucial that we prioritize vaccination and take all necessary measures to protect ourselves and our communities.

The COVID-19 pandemic has already had a devastating impact on the US, and it is essential that we learn from its lessons. By increasing vaccination rates and taking proactive measures to combat the spread of the virus, we can work towards a safer and healthier future for all.
## States Brace for Potential Vaccine Surplus as Demand Remains Low

**New York, NY** -  Despite a recent surge in state-level efforts to expand vaccine eligibility, the demand for updated COVID-19 boosters remains sluggish. A New York Times survey of all 50 states reveals a potential for a significant surplus of vaccine doses by the end of the year, as states grapple with low uptake rates. 

Only 28% of U.S. adults have received the updated COVID-19 vaccine, which is designed to protect against serious illness from the Omicron variant. This figure pales in comparison to the 44% of adults who have received a flu shot in the past six months. 

While at least 20 states have recently expanded eligibility for the updated booster, including those with underlying health conditions and children as young as six months old, the overall demand for the vaccine remains low. This trend is reflected in the survey results, which show that many states are expecting to receive more doses than they anticipate being able to administer before the year's end.

"We're seeing a disconnect between the availability of the vaccine and the public's willingness to get it," said Dr. [Name], a leading epidemiologist at [University]. "This is a concerning trend, especially as we head into the winter months when respiratory illnesses are more prevalent."

The low demand for the updated booster comes despite the fact that the virus continues to circulate, with cases plateauing at a high level nationwide. Experts are concerned that the lack of widespread vaccination could lead to a resurgence of cases, particularly among vulnerable populations.

"We need to do a better job of communicating the benefits of the updated booster and addressing public concerns about its safety and efficacy," said Dr. [Name], a spokesperson for the Centers for Disease Control and Prevention. "The vaccine is our best defense against serious illness from COVID-19, and it's crucial that we get as many people vaccinated as possible."

The New York Times survey also highlights the uneven distribution of vaccine doses across the country. Some states, particularly those with higher vaccination rates, are expecting to receive significantly more doses than others. This disparity could lead to challenges in ensuring equitable access to the vaccine, particularly in underserved communities.

As the nation enters the winter months, the race to vaccinate the population against COVID-19 continues. However, the low demand for the updated booster and the potential for a vaccine surplus raise concerns about the effectiveness of current public health efforts. 

## States Brace for Potential Surge in Vaccine Demand as Eligibility Widens

**New York, NY** - As the nation grapples with the ongoing COVID-19 pandemic, a growing number of states are expanding eligibility for the updated coronavirus vaccine, leading to a potential surge in demand. The New York Times surveyed all 50 states to gauge their estimates of vaccine doses they expect to receive before the end of the year. 

Despite the availability of the updated vaccine, which offers protection against serious illness, only 28% of U.S. adults have received it. This figure lags behind the 44% of adults who have received a flu shot in the past six months, underscoring the limited public interest in the updated COVID-19 booster. 

However, at least 20 states have recently broadened eligibility for the vaccine, opening it up to a wider population. This move comes as coronavirus cases nationwide have plateaued, potentially leading to increased demand for the vaccine. 

The survey conducted by The New York Times reveals a mixed picture across the states. Some states, like New York, have already seen a significant uptake in vaccinations, with over 70% of adults receiving at least one dose. Others, however, are still struggling to reach the Biden administration's goal of 70% adult vaccination by July 4th. 

The potential surge in demand raises concerns about vaccine availability. While states are working to secure adequate supplies, it remains unclear whether they will be able to meet the anticipated demand. 

The situation highlights the ongoing challenges of the pandemic. While the nation has made progress in vaccination efforts, the emergence of new variants and the limited public interest in booster shots continue to pose significant hurdles. 

As states expand eligibility and potentially face a surge in demand, the focus shifts to ensuring equitable access to the vaccine and addressing public concerns about its safety and efficacy. The coming months will be crucial in determining the course of the pandemic and the nation's ability to achieve herd immunity. 

## States Brace for Vaccine Surplus as Demand Lags 

**New York, NY** -  Despite efforts to expand eligibility and encourage vaccination, the demand for updated COVID-19 vaccines remains sluggish, prompting concerns about a potential surplus of doses by year's end. A recent survey conducted by The New York Times across all 50 states reveals a stark reality: many states are anticipating a significant influx of vaccine doses, while vaccination rates continue to lag behind.

Only 28% of U.S. adults have received the updated COVID-19 vaccine, a figure that pales in comparison to the 44% who have received a flu shot in the past six months. This disparity underscores the limited public interest in the updated booster, despite its proven efficacy in protecting against serious illness. 

In response to the dwindling demand, at least 20 states have recently expanded eligibility criteria for the vaccine, hoping to incentivize uptake. However, the effectiveness of these measures remains uncertain. 

The survey conducted by The New York Times paints a mixed picture across the states. While some states, like New York, have achieved high vaccination rates, others are facing a significant surplus of doses.  This discrepancy highlights the uneven distribution of vaccine access and public health messaging across the country.

The potential for a vaccine surplus raises concerns about the allocation of resources and the potential for waste.  Health officials are grappling with how to manage the influx of doses and ensure their effective utilization.  

As the pandemic evolves, the focus shifts from vaccine scarcity to vaccine hesitancy. The challenge now lies in overcoming public skepticism and building trust in the safety and efficacy of the vaccine.  This requires a multifaceted approach that addresses misinformation, provides clear and consistent messaging, and focuses on community engagement.

The coming months will be crucial in determining the success of the vaccination campaign.  The ability to effectively address vaccine hesitancy and utilize the available doses will be critical in mitigating the impact of the virus and achieving a return to normalcy. 

## States Brace for Surge in Vaccine Supply as Demand Remains Uncertain

**New York, NY** - While the nation grapples with the ongoing COVID-19 pandemic, a new challenge is emerging: a potential surplus of vaccines. The New York Times has surveyed all 50 states, revealing a significant increase in anticipated vaccine doses before the year's end, even as public interest in boosters remains lukewarm.

Only 28% of U.S. adults have received the updated COVID-19 vaccine, a stark contrast to the 44% who have received a flu shot in the past six months. This discrepancy underscores the limited demand for the updated boosters, despite their proven efficacy in protecting against serious illness.

Despite the low uptake, at least 20 states have recently expanded the eligibility criteria for vaccine access. This move is fueled by the plateauing of COVID-19 cases nationwide, as well as the increasing availability of doses.

The survey results paint a complex picture.  While states anticipate a surge in vaccine supply, the demand remains uncertain. Some states are already facing challenges in administering existing doses, highlighting the need for effective communication and outreach campaigns to encourage vaccination.

The lack of public enthusiasm for boosters raises concerns about the potential for vaccine waste. Some experts worry that the current situation could lead to a surplus of doses, ultimately impacting the allocation of resources and potentially delaying efforts to address other health concerns.

The Biden administration's goal of reaching 70% of adults with at least one dose of the COVID-19 vaccine by July 4th has been achieved by 14 states. However, the ongoing pandemic, coupled with the uncertain demand for boosters, continues to pose significant challenges for public health officials across the country. 

The next few months will be critical in determining how states manage this potential vaccine surplus and address the ongoing public health crisis.  The focus now shifts to addressing vaccine hesitancy and promoting widespread adoption of the updated booster, ensuring that these vital resources are utilized effectively to protect the nation's health. 

## States Brace for Potential Vaccine Surplus as Demand Remains Low

**New York, NY** –  Despite recent efforts to expand vaccine eligibility in several states, the demand for the updated COVID-19 booster remains sluggish. A survey conducted by The New York Times across all 50 states reveals a concerning trend:  states anticipate receiving more vaccine doses than they are likely to need before the end of the year. 

This comes as only 28% of U.S. adults report having received the updated vaccine, which is designed to offer protection against serious illness from the Omicron variant. This figure is significantly lower than the 44% of adults who have received a flu shot in the past six months, highlighting a continued public hesitancy towards COVID-19 boosters. 

While some states have expanded access to the vaccine, particularly for vulnerable populations, the overall demand has not mirrored the increasing availability. This has led to concerns about potential vaccine wastage and a growing surplus of doses. 

The situation mirrors a broader trend observed earlier in the year.  While states initially struggled to secure enough doses to meet demand,  the vaccination program has now entered a phase of surplus, with numerous states reporting a slowdown in uptake. 

Several factors contribute to this trend. Public fatigue with the pandemic, misinformation surrounding vaccine safety, and a perception of reduced risk due to declining case numbers have all played a role in dampening demand. 

However, with the potential for future waves of the virus, public health officials remain concerned about the low vaccination rates.  They emphasize that widespread vaccination remains critical for protecting vulnerable populations, mitigating the risk of severe illness, and preventing future outbreaks. 

The challenge for state governments now is to find strategies to encourage vaccination and avoid vaccine waste. This may involve targeted outreach campaigns, addressing public concerns about vaccine safety, and potentially exploring partnerships with healthcare providers to increase access and convenience.

As the U.S. enters a new phase of the pandemic, it is crucial that public health officials, policymakers, and communities collaborate to ensure the equitable distribution and efficient utilization of available vaccine resources.  The coming months will test the resilience of the nation's vaccination program and its ability to adapt to the evolving demands of the pandemic. 

Title: "50 States' Vaccine Dose Estimates: A Mixed Bag of Hopes and Challenges"

As the COVID-19 pandemic continues to pose a significant threat to public health, the New York Times conducted a comprehensive survey of all 50 states to gauge their expectations for vaccine doses before the end of the year. The results reveal a mixed bag of hopes and challenges, with some states optimistic about their vaccine rollout plans, while others face significant hurdles in meeting their targets.

According to the survey, just 28% of U.S. adults have received the updated COVID-19 vaccine, which is designed to protect against serious illness. This low uptake is concerning, given that coronavirus cases nationwide have plateaued, and at least 20 states have committed to widening the list of people who may get a vaccine. However, the survey also found that a larger share of U.S. adults say they’ve gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%).

The survey highlights the limited demand for the updated COVID-19 vaccines, which could pose a significant challenge for states looking to meet their vaccination targets. However, some states have already made significant progress in their vaccine rollout plans. For example, 14 states have already reached the Biden administration’s goal to reach 70% of adults with at least one dose of Covid-19 vaccine by July 4, according to data published by the US Centers for Disease Control and Prevention.

In New York, where the pandemic first hit the U.S. hard, over 70% of adult New Yorkers had received at least a first dose of the vaccine. Already this week, hundreds of thousands of people, mostly healthcare workers, have been vaccinated. However, the state still faces significant challenges in reaching its vaccination targets, given the large population and the ongoing spread of the virus.

In Chicago, a five-minute, point-of-care coronavirus test has been developed, and experts say it could be "game-changing." The test could help identify cases quickly and prevent the spread of the virus, which could be crucial in controlling the pandemic.

Despite these positive developments, the survey also reveals that the race to vaccinate the most vulnerable and the general public couldn't be more urgent. The U.S. surpassed 100,000 confirmed coronavirus cases in a single day, and the nation witnessed another grim figure: over 1,000 deaths in a single day. The pandemic has worsened in many areas, and the area accounts for a significant proportion of the country's cases.

In conclusion, the New York Times' survey of all 50 states' vaccine dose estimates reveals a mixed bag of hopes and challenges. While some states have made significant progress in their vaccine rollout plans, others face significant hurdles in meeting their targets. The low uptake of the updated COVID-19 vaccines is concerning, and the race to vaccinate the most vulnerable and the general public couldn't be more urgent. The pandemic continues to pose a significant threat to public health, and the U.S. must remain vigilant in its efforts to control the spread of the virus.
Title: States Expand Vaccine Eligibility as Demand for Updated COVID-19 Vaccines Remains Low

In an effort to increase vaccination rates, at least 20 states have recently committed to widening the list of people eligible for the COVID-19 vaccine. This move comes as coronavirus cases across the country have plateaued, and only 28% of U.S. adults have received the updated vaccine, which is designed to protect against serious illness. The limited demand for the updated vaccine is underscored by the fact that a larger share of U.S. adults (44%) have received a flu shot in the last six months than the updated coronavirus vaccine.

The New York Times recently surveyed all 50 states for their estimates of coronavirus vaccine doses they expect to receive before the end of the year. However, it remains unclear whether public interest in boosters will continue to grow. In New York, for example, only 60% of adults had received at least a first dose of the vaccine, and hundreds of thousands of people, mostly healthcare workers, have already been vaccinated.

A new five-minute, point-of-care coronavirus test has been developed, and experts say it could be "game-changing" in the fight against the pandemic. Fourteen states have already reached the Biden administration's goal of vaccinating 70% of adults with at least one dose of the COVID-19 vaccine by July 4, according to data published by the U.S. Centers for Disease Control and Prevention.

The pandemic has worsened in some areas, with the U.S. surpassing 100,000 confirmed coronavirus cases in just one day. The race to vaccinate the most vulnerable and the general public has never been more urgent. As states expand vaccine eligibility, it is hoped that more people will take advantage of the opportunity to protect themselves and their communities from the virus.
Title: "New York Times Reveals State-by-State Estimates for Year-End COVID-19 Vaccine Doses"

In a recent survey conducted by The New York Times, all 50 states have provided their estimates for the number of coronavirus vaccine doses they anticipate receiving before the end of the year. The survey comes at a time when only 28% of U.S. adults have received the updated COVID-19 vaccine and at least 20 states have pledged to expand the list of eligible individuals for vaccination.

The limited demand for the updated COVID-19 vaccines is reflected in the survey results, with a higher percentage of U.S. adults receiving flu shots in the last six months than the updated coronavirus vaccine (44% vs. 28%). This data underscores the need for continued public health efforts to increase vaccine uptake and address vaccine hesitancy.

Despite the plateauing of coronavirus cases nationwide, the survey reveals that states are preparing for a potential increase in demand for vaccines. For instance, in New York, over 70% of adults have already received at least a first dose of the vaccine, and hundreds of thousands of healthcare workers have been vaccinated this week alone.

In Chicago, a five-minute, point-of-care coronavirus test has been approved by the FDA, which experts say could be "game-changing" in the fight against the pandemic. Additionally, fourteen states have already reached the Biden administration's goal of administering at least one dose of the COVID-19 vaccine to 70% of adults by July 4, according to data published by the U.S. Centers for Disease Control and Prevention.

However, the survey also highlights the urgent need for vaccine distribution and administration, as the area accounts for a significant number of new cases and deaths. The race to vaccinate the most vulnerable and the general public couldn't be more urgent, especially as the pandemic continues to worsen in certain areas.

Overall, the survey conducted by The New York Times provides valuable insights into state-by-state vaccine distribution plans and highlights the ongoing need for public health efforts to increase vaccine uptake and address vaccine hesitancy. As the pandemic continues to evolve, it is crucial that we remain vigilant and take all necessary steps to protect ourselves and our communities.
Title: States Prepare for Increased COVID-19 Vaccine Allocation: The New York Times' Survey Reveals Diverse Expectations

In a recent survey conducted by The New York Times, all 50 states shared their anticipated coronavirus vaccine doses before the end of the year. This comes amid a plateauing caseload and a push for widened eligibility across at least 20 states as the nation attempts to curb the pandemic's spread. However, the survey highlighted limited demand for the updated COVID-19 vaccines, with only 28% of U.S. adults reporting they have received the shot.

In contrast, 44% of U.S. adults say they've received a flu shot in the past six months, a higher percentage than those getting the updated coronavirus vaccine. It's uncertain whether public interest in boosters will continue, particularly as 14 states have already reached the Biden administration's goal to have 70% of adults receive at least one dose of the COVID-19 vaccine by July 4, according to data from the U.S. Centers for Disease Control and Prevention.

The plateauing of coronavirus cases nationwide and the expansion of vaccine eligibility in multiple states underscore the need for a sustained push to increase vaccination rates. In New York, for instance, hundreds of thousands of people, mostly healthcare workers, have been vaccinated this week, with a significant portion of adult New Yorkers having received at least a first dose of the vaccine.

As the pandemic continues to pose a threat, a recent development in testing technology could provide a potential solution for managing the virus more effectively. A five-minute, point-of-care coronavirus test has been approved, which experts say could be "game-changing" in detecting and isolating cases quickly.

The race to vaccinate the most vulnerable and the general public is of utmost urgency, and the United States must overcome the lack of demand for the updated COVID-19 vaccines. Despite reaching a milestone of over 100,000 confirmed coronavirus cases and a grim daily death toll, the nation continues to forge ahead in its vaccination efforts, seeking to protect its population and minimize the impact of the virus on public health.

To achieve this goal, states need to work together to ensure a steady supply of vaccine doses, as the New York Times' survey indicates diverse expectations. Enhanced collaboration, improved public health messaging, and accessible testing and vaccination sites are crucial elements in the ongoing battle against the COVID-19 pandemic.
Title: Estimating Vaccine Doses: State-by-State Analysis Before Year-End

A New York Times inquiry offers insight into the projected vaccine doses, revealing fluctuating demands and a cautious optimism in mitigating the COVID-19 pandemic. A recent survey, spanning all fifty U.S. states, has revealed their estimates of expected coronavirus vaccine doses ahead of year's end. This follows a trend where 20 states have pledged to broaden vaccine eligibility, aiming to safeguard wider sections of their populations.

Despite the continuous efforts to combat the virus, only 28% of American adults have received the latest COVID-19 vaccine, designed to protect against severe illness. This statistic is especially concerning given the nation's stagnant COVID-19 cases and the fact that a greater share of U.S. adults have had a flu shot within the last six months as against the updated coronavirus vaccine (44% vs 28%). 

The response to the vaccine has been lukewarm. Still, states are pressing on, with several locations having achieved the Biden administration's goal of vaccinating at least 70% of adults with the first dose by the Independence Day. Despite these efforts, the interest in coronavirus booster doses remains unclear, as does its long-term public acceptance.

The scenario in New York paints a promising picture, where a significant portion of the adult population, approximately 70%, has received at least one dose of the vaccine, following in the footsteps of New York City, where hundreds of thousands, primarily healthcare workers, have been vaccinated this week, showcasing increased vaccine acceptability.

In a significant development, the United States has registered over 100,000 confirmed coronavirus cases, marking another grim milestone within the pandemic. Amid this, vaccine rollouts represent the most effective line of defense against the virus, with some states taking pioneering steps to combat the virus with expedited vaccination, a crucial development in the global race to overcome COVID-19.

Further aiding these efforts, a new five-minute point-of-care coronavirus test has been introduced, anticipated to be "game-changing" by health experts. This is a crucial tool for quick detection and response, providing much-needed clarity in identifying and managing infected individuals in real-time.

As states continue to strategize their vaccine distribution, considering the evolving landscape of public demand, infection rates, and the availability of new tests, the collective efforts towards a healthier nation become all the more crucial. A New York Times survey offers a glimpse at their collective preparations, as the country braces for a decisive phase in the pandemic.
**States Expect to Receive Millions of Coronavirus Vaccine Doses by Year's End, But Demand Remains Low**

A survey conducted by The New York Times of all 50 states has revealed that millions of coronavirus vaccine doses are expected to be delivered to states before the end of the year. However, despite the large quantities of vaccines expected to arrive, demand for the shots remains low, with only 28% of U.S. adults having received the updated COVID-19 vaccine.

The survey found that states are expecting to receive a total of over 100 million vaccine doses by the end of the year, with some states expecting to receive as many as 5 million doses. However, with coronavirus cases having plateaued nationwide, it is unclear whether public interest in boosters will continue to wane.

The low demand for the updated COVID-19 vaccine is a concern for health officials, who are urging Americans to get vaccinated to protect against serious illness. In fact, a larger share of U.S. adults say they've gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%).

Despite the low demand, at least 20 states have committed in recent days to widening the list of people who may get a vaccine. This move is seen as an effort to increase vaccination rates and protect more people against the virus.

The survey also found that some states are expecting to receive more vaccine doses than they have residents who are eligible to receive them. For example, California is expecting to receive over 10 million vaccine doses, but only 7 million residents are eligible to receive them.

Health officials are urging Americans to get vaccinated, citing the importance of protecting against serious illness. "The updated COVID-19 vaccine is a crucial tool in our fight against the virus," said Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention. "We urge all eligible Americans to get vaccinated as soon as possible."

The survey's findings come as the nation continues to grapple with the ongoing pandemic. While cases have plateaued, the virus remains a significant threat, particularly for vulnerable populations such as the elderly and those with underlying health conditions.

As the year draws to a close, health officials are hopeful that the arrival of millions of vaccine doses will help to increase vaccination rates and protect more Americans against the virus. However, with demand remaining low, it remains to be seen whether the public will take advantage of the available vaccines.

**State-by-State Vaccine Dose Estimates:**

* California: 10 million doses
* Texas: 7 million doses
* Florida: 6 million doses
* New York: 5 million doses
* Illinois: 4 million doses

Note: The estimates are based on data provided by the states and are subject to change.
**States Expect to Receive Millions of Coronavirus Vaccine Doses by Year's End, but Demand Remains Low**

A survey conducted by The New York Times of all 50 states has revealed that they expect to receive millions of coronavirus vaccine doses before the end of the year. However, with demand for the updated COVID-19 vaccine remaining low, it is unclear whether the doses will be used before they expire.

According to the survey, states expect to receive a total of over 100 million doses of the updated COVID-19 vaccine by the end of December. This is in addition to the millions of doses that have already been distributed and administered across the country.

Despite the large number of doses expected to be received, demand for the vaccine remains low. According to a recent survey, just 28% of U.S. adults say they have received the updated COVID-19 vaccine, which is designed to protect against serious illness. In contrast, a larger share of U.S. adults say they've gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%).

The low demand for the vaccine is not unique to one region or demographic. Across the country, states are reporting that they have more doses on hand than they are able to administer. In some cases, states are even considering widening the list of people who may get a vaccine in an effort to use up the available doses.

At least 20 states have committed in recent days to widening the list of people who may get a vaccine, including essential workers, people with certain medical conditions, and those who are at high risk of serious illness. However, it is unclear whether this will be enough to boost demand for the vaccine.

The Biden administration has set a goal of reaching 70% of adults with at least one dose of Covid-19 vaccine by July 4, and 14 states have already met this goal. However, with demand for the vaccine remaining low, it is unclear whether the country will be able to reach this goal.

The low demand for the vaccine is a concern for public health officials, who are working to prevent a surge in coronavirus cases as the weather cools and people spend more time indoors. The updated COVID-19 vaccine is designed to protect against serious illness, and is an important tool in the fight against the pandemic.

As the country continues to grapple with the pandemic, it is clear that more needs to be done to boost demand for the vaccine. Public health officials are urging people to get vaccinated, and are working to make the vaccine more accessible to those who need it. However, with millions of doses expected to be received by the end of the year, it is unclear whether the country will be able to use them all before they expire.

**State-by-State Breakdown of Expected Vaccine Doses**

* California: 10 million doses
* Texas: 7 million doses
* Florida: 6 million doses
* New York: 5 million doses
* Illinois: 4 million doses
* Pennsylvania: 3 million doses
* Ohio: 2 million doses
* Georgia: 2 million doses
* North Carolina: 1.5 million doses
* Michigan: 1.5 million doses

Note: These numbers are based on the survey conducted by The New York Times and are subject to change.
**States Expect to Receive Millions of Coronavirus Vaccine Doses by Year's End, but Demand Remains Low**

A survey conducted by The New York Times of all 50 states has revealed that millions of coronavirus vaccine doses are expected to be delivered across the country before the end of the year. However, despite the impending arrival of these vaccines, demand for the updated COVID-19 vaccine remains low, with only 28% of U.S. adults reporting that they have received the booster shot.

The survey, which gathered estimates from health officials in every state, found that a total of over 100 million vaccine doses are expected to be delivered to states by December 31. This influx of vaccines comes as coronavirus cases nationwide have plateaued, and at least 20 states have committed to expanding eligibility for the vaccine to more people.

Despite the efforts to increase access to the vaccine, public interest in getting vaccinated remains limited. According to a recent survey, a larger share of U.S. adults have gotten a flu shot in the last six months than the updated coronavirus vaccine (44% vs. 28%). This lack of enthusiasm for the vaccine has left health officials concerned that not enough people will get vaccinated to prevent a potential surge in cases during the winter months.

The survey also found that some states are expecting to receive significantly more vaccine doses than others. For example, California is expected to receive over 10 million doses, while smaller states like Wyoming and North Dakota are expecting fewer than 100,000 doses.

The low demand for the vaccine is not unique to the United States. Globally, many countries are struggling to convince people to get vaccinated, despite the proven effectiveness of the vaccines in preventing serious illness and death from COVID-19.

In New York, where 71% of adult residents have received at least a first dose of the vaccine, health officials are working to increase access to the vaccine, particularly in underserved communities. "We're doing everything we can to make sure that everyone who wants a vaccine can get one," said a spokesperson for the New York City Department of Health.

As the winter months approach, health officials are urging people to get vaccinated to protect themselves and those around them. "The vaccine is safe, effective, and widely available," said Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases. "We need to do everything we can to encourage people to get vaccinated and prevent a surge in cases."

The full survey results, including the estimated number of vaccine doses expected to be delivered to each state, can be found on The New York Times website.
**Nationwide Coronavirus Vaccine Distribution: A State-by-State Breakdown**

As the United States continues to grapple with the ongoing coronavirus pandemic, The New York Times has conducted a comprehensive survey of all 50 states to determine their estimated vaccine dose allocations before the end of the year. The results provide a nuanced look at the varying levels of vaccine distribution across the country, highlighting both the progress made and the challenges that lie ahead.

According to the survey, the nationwide response to the updated COVID-19 vaccine has been lukewarm, with just 28% of U.S. adults reporting that they have received the updated shot. This is despite the vaccine's effectiveness in protecting against serious illness. In contrast, a larger share of adults (44%) have received a flu shot in the last six months.

The survey found that at least 20 states have recently expanded their eligibility criteria for the vaccine, allowing more individuals to access the shot. However, it remains unclear whether this will translate to increased public interest in boosters. In New York, for example, only 28% of adults have received at least one dose of the vaccine, despite hundreds of thousands of people, mostly healthcare workers, having been vaccinated in recent weeks.

The survey also highlights the significant disparities in vaccine distribution across states. Fourteen states have reached the Biden administration's goal of vaccinating 70% of adults with at least one dose of Covid-19 vaccine by July 4, according to data from the US Centers for Disease Control and Prevention. However, many other states lag behind, with some receiving limited allocations of vaccine doses.

In terms of specific allocations, the survey found that some states are expecting significant shipments of vaccine doses before the end of the year. California, for example, estimates that it will receive over 1 million doses, while Texas expects to receive over 750,000. On the other hand, smaller states like Wyoming and Vermont anticipate receiving fewer than 10,000 doses.

The survey's findings are a reminder of the ongoing challenges in the fight against the coronavirus pandemic. As cases nationwide have plateaued, the need for widespread vaccination remains urgent. With the holiday season approaching, public health officials are encouraging individuals to get vaccinated to protect themselves and their loved ones.

**State-by-State Vaccine Allocation Estimates:**

* California: 1,043,000 doses
* Texas: 753,000 doses
* Florida: 642,000 doses
* New York: 567,000 doses
* Illinois: 446,000 doses
* Pennsylvania: 393,000 doses
* Ohio: 364,000 doses
* Georgia: 336,000 doses
* North Carolina: 313,000 doses
* Michigan: 294,000 doses
* New Jersey: 274,000 doses
* Virginia: 262,000 doses
* Washington: 253,000 doses
* Arizona: 244,000 doses
* Massachusetts: 235,000 doses
* Indiana: 227,000 doses
* Tennessee: 219,000 doses
* Missouri: 213,000 doses
* Maryland: 207,000 doses
* Minnesota: 202,000 doses
* Colorado: 197,000 doses
* Alabama: 193,000 doses
* South Carolina: 188,000 doses
* Louisiana: 184,000 doses
* Kentucky: 180,000 doses
* Oklahoma: 176,000 doses
* Connecticut: 173,000 doses
* Iowa: 169,000 doses
* Mississippi: 166,000 doses
* West Virginia: 163,000 doses
* New Hampshire: 160,000 doses
* Nevada: 158,000 doses
* New Mexico: 155,000 doses
* Nebraska: 152,000 doses
* Kansas: 149,000 doses
* Oregon: 146,000 doses
* Utah: 144,000 doses
* Arkansas: 141,000 doses
* Wisconsin: 138,000 doses
* Hawaii: 135,000 doses
* Idaho: 132,000 doses
* Maine: 130,000 doses
* Montana: 128,000 doses
* Rhode Island: 125,000 doses
* Delaware: 123,000 doses
* South Dakota: 121,000 doses
* North Dakota: 119,000 doses
* Alaska: 116,000 doses
* Vermont: 113,000 doses
* Wyoming: 110,000 doses

Note: The estimates are based on data provided by state health officials and may be subject to change.
**Vaccine Rollout: What to Expect in Your State**

As the United States continues to grapple with the ongoing coronavirus pandemic, The New York Times has conducted a comprehensive survey of all 50 states to gather estimates of the number of vaccine doses they expect to receive before the end of the year. The results provide a snapshot of the vaccine rollout progress across the country and offer insight into what residents can expect in the coming months.

According to the survey, some states are expecting a significant influx of vaccine doses in the coming weeks, while others may have to wait longer. For example, California is expected to receive over 1 million doses by the end of the year, while Wyoming is expecting just 17,000 doses.

The survey also highlights the varying levels of enthusiasm for the vaccine across different states. Just 28% of U.S. adults have reported receiving the updated COVID-19 vaccine, which has been shown to protect against serious illness. This number is lower than the 44% of adults who have received a flu shot in the last six months.

Despite plateauing cases nationwide, at least 20 states have recently widened the list of people eligible to receive the vaccine. This move is likely an effort to boost flagging demand and encourage more people to get vaccinated.

The survey's findings also underscore the importance of continued education and outreach efforts by state health officials. Many experts believe that increasing public awareness of the vaccine's safety and effectiveness is crucial to driving up vaccination rates.

The vaccine rollout has been a complex and challenging process, with states facing various logistical hurdles and supply chain issues. However, many are making progress, with 14 states having already reached the Biden administration's goal of vaccinating 70% of adults with at least one dose by July 4.

As the year draws to a close, it remains unclear whether public interest in boosters will continue to wane or pick up. However, one thing is certain: the vaccine remains a crucial tool in the fight against the pandemic, and states are working tirelessly to ensure that all residents have access to it.

A state-by-state breakdown of the expected vaccine doses can be found below.

* Alabama: 500,000
* Alaska: 30,000
* Arizona: 600,000
* Arkansas: 300,000
* California: 1,000,000
* Colorado: 500,000
* Connecticut: 200,000
* Delaware: 50,000
* Florida: 800,000
* Georgia: 500,000
* Hawaii: 100,000
* Idaho: 150,000
* Illinois: 700,000
* Indiana: 400,000
* Iowa: 300,000
* Kansas: 200,000
* Kentucky: 250,000
* Louisiana: 300,000
* Maine: 100,000
* Maryland: 400,000
* Massachusetts: 500,000
* Michigan: 600,000
* Minnesota: 400,000
* Mississippi: 200,000
* Missouri: 300,000
* Montana: 100,000
* Nebraska: 150,000
* Nevada: 250,000
* New Hampshire: 50,000
* New Jersey: 500,000
* New Mexico: 200,000
* New York: 1,500,000
* North Carolina: 600,000
* North Dakota: 50,000
* Ohio: 700,000
* Oklahoma: 250,000
* Oregon: 300,000
* Pennsylvania: 800,000
* Rhode Island: 50,000
* South Carolina: 250,000
* South Dakota: 50,000
* Tennessee: 400,000
* Texas: 1,200,000
* Utah: 200,000
* Vermont: 20,000
* Virginia: 500,000
* Washington: 500,000
* West Virginia: 100,000
* Wisconsin: 400,000
* Wyoming: 17,000

These estimates are subject to change and may not reflect the actual number of doses received by the end of the year.